SCHEMBL21749275

SCHEMBL21749275

CC(C)(C)N(C(=O)O)S(=O)(=O)NCCn1nnc(-c2ccccc2Nc2ccc(C(F)(F)F)cc2)n1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 9/20 0.43
▸ TP53 P04637 1/20 0.40
▸ ABCB1 P08183 2/20 0.39
▸ DDX3X O00571 1/20 0.39
▸ LMNA P02545 4/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ KMT2A Q03164 5/20 0.39
▸ SMN1; SMN2 Q16637 5/20 0.39
▸ MEN1 O00255 4/20 0.39
▸ MAPT P10636 3/20 0.39
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ TSHR P16473 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20552371 0.85 ABCG2 (0.42) ABCG2TP53ABCB1DDX3XLMNA
SCHEMBL20552762 0.84 ABCG2 (0.46) ABCG2TP53ABCB1DDX3XLMNA
SCHEMBL20551720 0.83 ABCG2 (0.42) ABCG2TP53ABCB1DDX3XLMNA
SCHEMBL20552787 0.82 ABCG2 (0.50) ABCG2TP53ABCB1DDX3XLMNA
SCHEMBL21749264 0.82 ABCG2 (0.40) ABCG2TP53ABCB1DDX3XLMNA
SCHEMBL20552616 0.81 ABCG2 (0.47) ABCG2TP53ABCB1DDX3XLMNA
SCHEMBL20552483 0.80 DDX3X (0.46) ABCG2TP53ABCB1DDX3XLMNA
SCHEMBL20552969 0.80 ABCG2 (0.43) ABCG2TP53ABCB1DDX3XLMNA
SCHEMBL20551717 0.79 DDX3X (0.43) ABCG2TP53ABCB1DDX3XLMNA
SCHEMBL20552875 0.79 ABCG2 (0.53) ABCG2TP53ABCB1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186554-B2 Non-fused tricyclic compounds VIVACE THERAPEUTICS, INC. (US) 2021-11-30 — — US disclosed
US-20200062721-A1 NON-FUSED TRICYCLIC COMPOUNDS VIVACE THERAPEUTICS, INC. 2020-02-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062721-A1 NON-FUSED TRICYCLIC COMPOUNDS YAP1, MYC, TEAD2 ABCG2 3004/4885TP53 10/4885ABCB1 1774/4885
US-11186554-B2 Non-fused tricyclic compounds YAP1, MYC, TEAD2 ABCG2 3004/4885TP53 10/4885ABCB1 1774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback